Ocugen Secures Funding to Advance Key Gene Therapy Trials
Veröffentlicht: 30.01.2026 um 16:59 Uhr, Redaktion boerse-global.de
Biotechnology firm Ocugen has bolstered its financial position through a recent capital raise, providing crucial resources as it approaches significant clinical milestones. The company has extended its financial runway into the fourth quarter of 2026, securing $22.5 million in new funding. This strategic move comes at a pivotal moment for the company’s development pipeline.
On January 23, 2026, Ocugen completed the placement of 15 million new shares at $1.50 per share. After accounting for commissions and associated expenses, the net proceeds to the company are approximately $20.85 million. The capital raise was led by RTW Investments, with participation from both existing shareholders and new institutional investors.
Management has indicated that these funds are allocated for Read more...
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
